Molecular Partners Ag (MOLN) Interest & Investment Income (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly Interest & Investment Income of $395.87 for Q1 2026, down 29.1% year-over-year from $558.35 in Q1 2025, and up 100.01% quarter-over-quarter from -$4.4 million in Q4 2025.
Molecular Partners Ag (MOLN) Interest & Investment Income (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Interest & Investment Income for 7 consecutive years, with $395.87 the latest figure, recorded in Q1 2026.
- In Q1 2026, Interest & Investment Income fell 29.1% year-over-year to $395.87; the TTM figure through Mar 2026 stood at -$4.4 million (down 153.29% YoY), while the FY2025 annual figure was -$4.4 million, down 153.28% from the prior year.
- Interest & Investment Income rose to $395.87 in Q1 2026 per MOLN's latest filing, from -$4.4 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $8.2 million in Q4 2024 and bottomed at -$4.4 million in Q4 2025.
- Historically, Interest & Investment Income has averaged $817261.8 across 5 years, with a median of $1008.5 in 2024.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 840.27% — and 2025, when it plunged 153.33%.
- Molecular Partners Ag's Interest & Investment Income stood at $1.9 million in 2022, then jumped by 150.39% to $4.8 million in 2023, then jumped by 70.42% to $8.2 million in 2024, then tumbled by 153.33% to -$4.4 million in 2025, then soared by 100.01% to $395.87 in 2026.
- Business Quant data shows MOLN's Interest & Investment Income at $395.87 in Q1 2026, -$4.4 million in Q4 2025, and $457.54 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - | 395.87 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 395.87 |
| Dec 31, 2025 | -4.38 Mn |
| Sep 30, 2025 | 457.54 |
| Jun 30, 2025 | 507.31 |
| Mar 31, 2025 | 558.35 |
| Dec 31, 2024 | 8.21 Mn |
| Sep 30, 2024 | 828.72 |
| Jun 30, 2024 | 1,008.48 |
| Mar 31, 2024 | 5,204.83 |
| Dec 31, 2023 | 4.82 Mn |
| Sep 30, 2023 | 2,333.37 |
| Jun 30, 2023 | 1.21 Mn |
| Mar 31, 2023 | 937.37 |
| Dec 31, 2022 | 1.93 Mn |
| Sep 30, 2022 | 1,539.72 |
| Jun 30, 2022 | 2.09 Mn |
| Mar 31, 2022 | 891.15 |
| Dec 31, 2021 | 204,749.66 |
| Sep 30, 2021 | 717.74 |
| Jun 30, 2021 | 1.69 Mn |